CFC MDI marketing by firms pursuing CFC-free alternatives should be allowed, Glaxo contends.
Executive Summary
CFC MDI MARKETING BY COMPANIES PURSUING CFC-FREE PRODUCTS SHOULD BE ALLOWED, Glaxo maintained in comments on FDA's proposed rule on the phase-out of chlorofluorocarbon-containing metered dose inhalers. "FDA should not ban a CFC product when its manufacturer is actively pursuing approval of a CFC-free alternative product containing the same active moiety as the CFC product," Glaxo Wellcome said.